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Pharmacogenetic 
Predictors
Systemic therapy for psoriasis 
is required in about 15% of 
patients. The use of the low-
cost first-line systemic drug 
methotrexate is complicated 
by intraindividual variation in 
efficacy and development of 
significant side effects. Warren 
and colleagues identified single-
nucleotide polymorphisms 
(SNPs) that correlated with 
methotrexate efficacy in two 
efflux transporters (ABCC1 and 
ABCG2) and with toxicity in 
ABCC1, the influx transporter 
SLC19A1, and the adenosine 
receptor ADORA2a. Thus, 
prediction of the effectiveness 
of methotrexate or other drugs 
can likely be derived from 
the combinations of SNPs in 
multiple genes involved in the 
action and metabolism of each 
drug. See page 1925
Antitumor Antiviral
In a follow-up prospective 
study, Kreuter and colleagues 
investigated the long-term 
effects of imiquimod, an 
antitumor and antiviral topical 
immune response modifier, on 
anal intraepithelial neoplasia 
(AIN) and high-risk human 
papillomavirus (HPV) infections 
in HIV-positive men who have 
sex with men (MSM). Notably, 
AIN did not recur during the 
follow-up period in 74% of the 
patients who were negative 
for AIN following imiquimod 
therapy. In addition, HPV loads 
in these men were decreased. 
These results support the use 
of routine imiquimod therapy, 
given that AIN is common 
among HIV-positive MSM and 
increases the risk of anal cancer. 
See page 2078
Allergens Disrupt Barrier
Mite allergens, which appear to exacer-
bate atopic dermatitis (AD), exhibit pro-
teolytic activity. Jeong and colleagues 
demonstrated that increased epidermal 
protease activity and subsequent acti-
vation of protease-activated receptor-2 
(PAR-2) by mite and cockroach allergens 
contributed to delayed barrier recovery in 
murine and human skin following repeat-
ed tape stripping. Treatment with protease 
inhibitors or a PAR-2-specific antagonist, 
however, facilitated typical barrier recov-
ery. Importantly, allergens induce allergic 
responses and, in addition, alter the homeostasis of the epidermal barrier in AD 
skin lesions. See page 1930
In the “Field”
Identification of “field” cells, which are 
genetically abnormal melanocytes in nor-
mal epidermis adjacent to sites of mela-
noma excision, prompted North and col-
leagues to investigate the mechanism of 
recurrent melanoma. Results from his-
tologic, genetic, and fluorescent in situ 
hybridization techniques indicated that 
these cells represent an early stage of 
melanoma in situ and can give rise to new 
lesions down the road. Although surgi-
cal excision margins are typically based 
on tumor thickness, this study revealed 
that the extent of the field effect does not actually correlate with the thickness of 
the primary melanoma, prompting new recommendations for surgical borders. 
See page 2024
Xeroderma Pigmentosum–Variant Variations
Xeroderma pigmentosum–variant (XP-V) is an 
autosomal recessive disorder characterized by 
sun sensitivity, increased incidence of skin cancer, 
and, unlike other XP subgroups, intact nucleotide 
excision repair. Inui and colleagues examined 15 
XP-V patients from 10 families in North America, 
Europe, and Asia and identified 10 different muta-
tions in the POLH gene, which encodes the DNA 
polymerase that is critical in translesional DNA 
synthesis. Splice site, nonsense, frameshift, and 
missense mutations were discovered, indicating a 
vast spectrum of mutations in this complementa-
tion group. Interestingly, the mutations failed to 
yield recognizable correlations with the clinical features of disease. See page 2055
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